Cardinal Strategic Wealth Guidance Sells 29 Shares of Eli Lilly and Company $LLY

Cardinal Strategic Wealth Guidance cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 611 shares of the company’s stock after selling 29 shares during the quarter. Cardinal Strategic Wealth Guidance’s holdings in Eli Lilly and Company were worth $476,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Grassi Investment Management raised its holdings in shares of Eli Lilly and Company by 0.3% in the 2nd quarter. Grassi Investment Management now owns 79,927 shares of the company’s stock valued at $62,305,000 after purchasing an additional 200 shares during the period. Corundum Group Inc. raised its holdings in shares of Eli Lilly and Company by 55.9% in the 2nd quarter. Corundum Group Inc. now owns 1,629 shares of the company’s stock valued at $1,270,000 after purchasing an additional 584 shares during the period. Segment Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 221.7% in the 2nd quarter. Segment Wealth Management LLC now owns 4,452 shares of the company’s stock valued at $3,470,000 after purchasing an additional 3,068 shares during the period. Fortis Capital Advisors LLC raised its holdings in shares of Eli Lilly and Company by 2.1% in the 2nd quarter. Fortis Capital Advisors LLC now owns 1,771 shares of the company’s stock valued at $1,381,000 after purchasing an additional 37 shares during the period. Finally, Precedent Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the period. 82.53% of the stock is owned by institutional investors.

Insider Activity

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on LLY shares. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Saturday, September 27th. Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $933.39.

Eli Lilly and Company Stock Up 2.5%

Eli Lilly and Company stock opened at $840.46 on Friday. The stock has a market cap of $795.47 billion, a P/E ratio of 54.93, a P/E/G ratio of 1.14 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company’s 50-day moving average price is $734.60 and its two-hundred day moving average price is $766.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.